CQN-AZ-SES
Second paragraph of release dated September 22, 2020 should read: The first MEO and Earth Observation gateways will be located in the United States; in Phoenix, Arizona and Quincy, Washington respectively. (instead of ... located in Phoenix, Arizona, United States and Quincy, Western Australia respectively).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005927/en/
The updated release reads:
SES BECOMES MICROSOFT AZURE ORBITAL FOUNDING CONNECTIVITY PARTNER
SES’s proven low-latency MEO managed services to be part of Microsoft’s new multi-orbit satellite connectivity integrated with Azure, promising optimized cloud application performance for O3b mPOWER customers
SES today announced it has joined as the medium Earth orbit (MEO) connectivity partner for Microsoft Azure Orbital, Microsoft’s new managed service enabling network operators to communicate and control their satellite capacity, process data, and scale their operations directly within Azure. The integration is part of a multi-year agreement between the two companies that accelerates and expands SES’s use of Azure to significantly advance the digital transformation of the company’s services and operations as part of its cloud-first strategy.
As pioneers in Microsoft’s new cloud ecosystem in space, the two companies will make joint investments in Azure Orbital ground stations that SES will deploy and manage for the MEO and Earth Observation segments. The first MEO and Earth Observation gateways will be located in the United States; in Phoenix, Arizona and Quincy, Washington respectively.
In anticipation of O3b mPOWER , SES’s next-generation MEO communications system, SES and Microsoft will seamlessly co-locate several telemetry, tracking and command (TT&C) systems and data ground stations with Microsoft’s Azure edge sites.
The integration of both SES and Azure networks will provide O3b mPOWER customers with “one-hop” access to their Azure cloud services. The option to route over Microsoft’s global network and inject value-added, cloud-based managed services such as enhanced security, SD-WAN, and other network functions into the service chain will mean that SES customers can enjoy improved network performance, speed-to-market, flexibility and scalability they need to capitalise on new revenue opportunities.
O3b mPOWER is SES’s next-generation MEO communications system. It is currently under construction and on track for launch in 2021. The high-throughput and low-latency satellites as well as automated and intelligence-powered ground infrastructure will deliver managed services of hundreds of Mbps up to multiple Gbps per second to customers.
Today’s agreement builds on the work started last year between the two companies, which added SES as an Azure ExpressRoute partner and SES as the first satellite operator to implement Open Network Automation Platform (ONAP) using NFV technology on Azure.
“In the last 12-18 months, our focus has been to accelerate our customers’ cloud adoption plans. We are pleased to have found an ideal partner in Microsoft with its new Azure Orbital system. This agreement leverages both companies’ know-how – SES's experience in satellite infrastructure and Microsoft’s cloud expertise – and are building blocks in developing new and innovative solutions for the future,” said JP Hemingway, CEO of SES Networks. “In addition to building and managing EOS gateways for Microsoft, we are also thrilled that we will be co-locating, deploying and operating our next-generation O3b mPOWER gateways alongside Microsoft’s data centres. This one-hop connectivity to the cloud from remote sites will enable our MEO customers to enhance their cloud application performance, optimise business operations with much flexibility and agility needed to expand new markets.”
“Our launch of Azure Orbital will enable our partners’ customers to on-ramp their data into Azure where it can immediately be processed with market-leading data analytics, geospatial tools and machine learning services, adding another layer of automation and intelligence in their networks,” said Jeff Cohen, Partner Program Manager, Azure Networking at Microsoft Corp. “In addition, SES’s O3b mPOWER communications system is proof of SES’s cloud-first strategy, focusing on industry standards and orchestration, and aligns with our connectivity vision for the future, and we are delighted to be kicking off this project.”
Follow us on:
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005927/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom